|
About
The Treatment Timebomb:
The
APPG Inquiry into long-term access to HIV treatment in the developing
world
The Inquiry Process
The
inquiry had three stages. Firstly, in February 2009 the APPG sent out a
call for evidence to all of its
contacts - it
received written responses from pharmaceutical companies, NGOs and
international foundations, such as the Clinton AIDS Initiative. Secondly,
the APPG convened a high-level round table in parliament for senior
charity HIV experts and pharmaceutical company officials, MPs and Peers. A
note on the meeting can be accessed
here. Finally, a
cross-party group of MPs and Peers visited Geneva to talk to the WHO,
UNAIDS, the Global Fund for AIDS, TB and malaria, and other relevant
organisations. More information about the visit can be found
here.
Click on the picture to download the report.
The Final Report
The
Treatment Timebomb, describes how by 2030 over 50 million people will need
HIV treatment compared to just 9 million who need it today.
Millions of those needing treatment in future will need more expensive
medicines, having become resistant to the basic HIV combination therapy.
These ‘second-line’ treatments currently cost at least seven times more.
When the basic treatment stops working, getting them is a matter of life
or death.
Some
people will also need to switch from the basic combination to newer
less-toxic drugs because they experience serious side effects.
The
combination of more people needing more complex treatment is, says the
report, a timebomb that needs to be addressed now, to avoid crisis later.
Governments around the world, including the UK, have signed up to the goal
of ‘Universal Access to HIV treatment, prevention, care and support’ by
2010. The world is not on track to meet this target with only a third of
the nine million people who need it having access to HIV treatment. This
is despite the fact that for now, most people are on the cheap therapy.
The
report argues that cutting the price of medicines is possible. Ten years
ago the basic HIV treatment cost over $10,000 per person, per year. Today,
thanks to generic production, these same medicines are available for just
$87 per person enabling 3 million people to be treated across the world.
It
says that to avoid
a treatment crisis these kind of price reductions need to happen again
with the newer HIV medicines. It urges pharmaceutical companies to
cooperate by allowing generic manufacturers to produce their HIV medicines
cheaply, specifically for developing countries. It asks them to put their
patents into a ‘patent
pool’ for this purpose. Over 100 MPs have also signed a motion asking
companies to do this. You can find out whether your MP has signed up
here.
The
‘patent pool’ would also allow researchers to work on making HIV medicines
suited to the developing world. Currently many HIV medicines are designed
for a developed country market and do not consider issues such as what
happens when a patient needs to take HIV medicines and TB medicines at the
same time. There are also not many special HIV drugs for children, because
hardly any children in the developed world have HIV.
In welcoming
the report, International Development Minister, Mike Foster, said:
““The
simple fact is that the HIV epidemic continues to outstrip our best
efforts. Five people are infected with HIV every minute and for every two
people put on treatment, there are 5 people newly infected with HIV.
This
important report reminds us that while it is absolutely vital that we work
to reduce the human cost of HIV by focusing our
efforts on preventing new infections, we must also face up to the stark
reality of the treatment challenge we face.
The
pharmaceutical industry has an opportunity to act now to help prevent
future human catastrophe. It is time for them to state their clear
commitment to make new HIV medicines affordable to those who need them
most, by working with UNITAID to develop a patent pool.”
The
Launch
The
report was launched on 14th July 2009 in Parliament, with speeches from
David Borrow MP, Chair of the APPG; Mike Foster, Parliamentary Under
Secretary of State for International Development; and Ellen T'Hoen from
the UNITAID Patent Pool in Geneva.
If you would like copies of the report to support your campaigning
activities please get in touch with the APPG.
|